Lung Cancer

Management of Small Cell Lung Cancer

Jacob Sands, MD
Molecular Testing and the Implications for 1L Therapy in Stage IV EGFRm NSCLC

Charu Aggarwal, MD, MPH
Advances in the Management of Stage III NSCLC –Impact of the LAURA Clinical Trial

Charu Aggarwal, MD, MPH
Advances in Recurrent NSCLC – Dato-DXd

Jacob Sands, MD
Advances in the Management of Extensive Small Cell Lung Cancer

Stephen V. Liu, MD
NTRK Fusions, What’s Next? A Discussion on the Current Landscape of NTRK Fusion Therapeutic Management

Martin F. Dietrich, MD, PhD
ASCO Conference Coverage – Lung Cancer

Charu Aggarwal, MD, MPH
Perioperative Therapy and esNSCLC – ALINA Improves Outcomes for ALK Mutated NSCLCs

Charu Aggarwal, MD, MPH; Eric Vallieres, MD
Perioperative Therapy in Early Stage NSCLC – Implications for Molecular Testing

Charu Aggarwal, MD, MPH; Brendon M. Stiles, MD
Emerging Role of Antibody Drug Conjugates (ADC) in Advanced NSCLC

Jacob Sands, MD
Adjuvant therapy for Early Stage Lung Cancer – Case Based Discussion for Patient with Stage 1B NSCLC

Charu Aggarwal, MD, MPH; John Kucharczuk, MD
Use of ctDNA for Molecular Residual Disease Assessment and Immunotherapy Monitoring in NSCLC

Natalie I. Vokes, MD, MPH